Oncovita

Pre-clinical

Paris, FranceFounded 2015oncovita.fr

Oncovita is a spin-off from Institut Pasteur dedicated to developing life-saving cancer treatments using its proprietary Measovir® platform, a modified measles virus vector. The company has secured exclusive worldwide licensing rights from Institut Pasteur and is advancing its lead candidate, MVdeltaC, for pleural mesothelioma, which has received FDA Orphan Drug Designation. Led by a seasoned management team, Oncovita is building a pipeline of oncolytic virus candidates and has established strategic partnerships with entities like Infinitusbio.AI and Unither Pharmaceuticals to accelerate development.

Founded

2015

Focus

BiologicsViral Technology

AI Company Overview

Technology Platform

The Measovir® platform is a proprietary reverse genetics system based on the live attenuated measles vaccine (Schwarz strain), engineered to create oncolytic viruses that specifically infect cancer cells via the CD46 receptor and induce immunogenic cell death.

Funding History

Total raised: $2.5M

Seed$2.5MUndisclosedJun 15, 2021

Opportunities

The massive unmet need in oncology and the growing acceptance of immuno-oncology create a significant opportunity for Oncovita's platform.

The 'plug-and-play' nature of Measovir® allows for rapid generation of new candidates for multiple cancer types, and the platform's application could extend beyond therapeutics into prophylactic vaccinology.

Risk Factors

As a preclinical company, Oncovita faces high technical risk in translating its science to the clinic.

Securing substantial funding for costly oncology trials is a major challenge.

The competitive landscape in oncolytic virotherapy is intensifying, requiring clear differentiation and robust clinical data.

Competitive Landscape

Oncovita competes in the oncolytic virus space with companies like Amgen (Imlygic), Replimune, and Turnstone Biologics. Its key differentiation is the use of the measles vaccine vector, which offers a unique safety profile, inherent CD46-mediated tumor targeting, and strong immunogenicity derived from a clinically validated backbone.